# Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease

> **NCT02648347** · PHASE3 · COMPLETED · sponsor: **Akebia Therapeutics** · enrollment: 1751 (actual)

## Conditions studied

- Anemia
- Non-Dialysis-Dependent Chronic Kidney Disease

## Interventions

- **DRUG:** Vadadustat
- **DRUG:** Darbepoetin alfa

## Key facts

- **NCT ID:** NCT02648347
- **Lead sponsor:** Akebia Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12
- **Primary completion:** 2020-06-04
- **Final completion:** 2020-07-31
- **Target enrollment:** 1751 (ACTUAL)
- **Last updated:** 2022-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02648347

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02648347, "Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02648347. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*